Vaginal Atrophy Clinical Trial
Official title:
EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY
Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing
17ß-estradiol.
The estradiol in estradiol vaginal tablet is chemically and biologically identical to the
endogenous human estradiol and is therefore classified as a human estrogen.
The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's
Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem®)which is
approved and marketed in the US.
Estradiol vaginal tablet is indicated for use in the treatment of symptoms of atrophic
vaginitis due to estrogen deficiency.
This is a randomized, observer blind, parallel groups, active and placebo controlled study to
test the clinical endpoint bioequivalence of test product (Estradiol vaginal tablet, 10mcg of
Sun Pharmaceutical Industries Ltd. India) relative to reference (Vagifem®, Estradiol vaginal
tablet, 10mcg estradiol of Novo Nordisk) in treatment of vulvar and vaginal atrophy.
The patients will be administered with one tablet intravaginally daily for 14 days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06136975 -
Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
|
||
| Recruiting |
NCT04081805 -
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
|
N/A | |
| Completed |
NCT04039555 -
Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER)
|
N/A | |
| Active, not recruiting |
NCT02704741 -
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
|
N/A | |
| Completed |
NCT01975129 -
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
|
Phase 2 | |
| Completed |
NCT04735549 -
Vulvovaginal Atrophy Correction Using Neodymium Laser
|
N/A | |
| Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
| Completed |
NCT03063684 -
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus
|
N/A | |
| Recruiting |
NCT05953090 -
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
|
N/A | |
| Not yet recruiting |
NCT05483634 -
Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause
|
||
| Completed |
NCT04717245 -
Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
|
N/A | |
| Completed |
NCT02967510 -
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
|
Phase 2 | |
| Completed |
NCT02937805 -
Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes
|
N/A | |
| Not yet recruiting |
NCT02571127 -
Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.
|
Phase 4 | |
| Completed |
NCT00238732 -
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
|
Phase 3 | |
| Completed |
NCT02413008 -
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
|
Phase 2 | |
| Completed |
NCT03493126 -
Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function
|
Phase 4 | |
| Not yet recruiting |
NCT03238053 -
Laser Treatment of Genito-urinary Syndrome in Women
|
N/A | |
| Terminated |
NCT05627791 -
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
|
Phase 2/Phase 3 | |
| Completed |
NCT00429806 -
DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy
|
Phase 1 |